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ABSTRACT
We describe a method to identify and recover
minor human immunodeficiency virus type 1 (HIV-1)
sequence variants from a complex population. The
original heteroduplex tracking assay (HTA) was
modified by incorporating a biotin tag into the
probe to allow for direct sequence determination of
the query strand. We used this approach to recover
sequences from minor HIV-1 variants in theV3 region
of the env gene, and to identify minor drug-resistant
variants in pro. The biotin-HTA targeting of the V3
region of env allowed us to detect minor V3 vari-
ants, of which 45% were classified as CXCR4-using
viruses. In addition, the biotin-protease HTA was
able to detect mixtures of wild-type sequence and
drug-resistance mutations in four subjects that
were not detected by bulk sequence analysis. The
biotin-HTA is a robust assay that first separates
genetic variants then allows direct sequence analy-
sis of major and minor variants.
INTRODUCTION
Genetically unstable organisms present a special challenge
to therapeutic intervention. Genetic instability coupled
with large population sizes leads to population diversity
that can harbor advantageous mutations in the face of
changing selective pressures. Our knowledge about genetic
complexity is always limited by our ability to sample
minor variants within the population. One example of
this phenomenon is the human immunodeﬁciency virus
type 1 (HIV-1), which maintains genetic diversity in its
population that can impact evolution of escape from
immune selection, drug resistance and changes in target
cell speciﬁcity (1).
Several approaches are available for sampling genetic
complexity. Bulk sequence analysis of the total population
suﬀers from limited sensitivity, and cannot reliably detect
variants that comprise less than  25% of the population
(2,3). A strategy of cloning a PCR product generated from
a complex population followed by sequencing individual
clones is limited by the number of clones analyzed, and
the accurate detection of minor variants in the population
requires a large sampling of clones (3,4). Allele-speciﬁc
PCR can detect variants in the 0.1–1% range, and
although there is no information about linkage to other
sequence variation (5,6), further analysis of the allele-
speciﬁc product can generate some linkage information
(7). More recent pyrosequencing approaches oﬀer deep
sequencing capability, although the high error rate neces-
sitates oversampling of sequences which reduces sensitiv-
ity, and bioinformatics approaches are necessary to handle
the large data output (8).
An alternative approach to dissecting genetic diversity
is the heteroduplex tracking assay (HTA). The HTA is
a gel-based assay that separates viral variants based on
sequence diﬀerences, and can resolve variants that com-
prise as little as 1–3% of the total viral population (9–11).
In this assay, the desired genomic region is ampliﬁed by
PCR, and a radioactively labeled probe is annealed to the
PCR products. Heteroduplexes are generated between
the probe and PCR products, and any insertions, deletions
or clustered mutations will result in a bend or kink in
the DNA helix, conferring an altered migration through
a nondenaturing polyacrylamide gel. However, this
approach is limited in that it is not linked to direct
sequence analysis.
In this report, we describe a modiﬁcation of the HTA
strategy that couples the ability to separate genetic var-
iants in a gel-based assay with direct sequence analysis
of the separated variants. The ability to directly sequence
the query strand of each heteroduplex in the gel was
accomplished by adding a biotinylated-nucleotide tag to
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probe, we were able to purify the labeled heteroduplex
and subsequently separate the query strand from the
probe. The puriﬁed query strand was then subjected to
PCR ampliﬁcation and conventional sequence analysis.
We used this approach to identify sequences from minor
variants in the V3 region of the HIV-1 env gene that pre-
dict changes in target cell tropism, and to examine the
heterogeneity of the pro gene population during the evolu-
tion of resistance to protease inhibitors.
MATERIALS AND METHODS
Plasmasamples
All plasma samples were obtained as excess tissue samples
and with Institutional Review Board approval. Samples
for the V3 studies were from subjects in a ritonavir eﬃcacy
study (12), and were provided by Dale Kempf (Abbott
Laboratories) unlinked to personal identiﬁers. Samples
for the protease studies were entry time-point plasma
samples obtained from subjects in the ACTG 359 clinical
trial (13).
Plasmids andprobes
The V3 Mut-1 probe plasmid was generated using the
V3JR-FL plasmid pJN27 developed by Nelson et al. (14).
A BamHI restriction site located upstream of the probe
insert in pJN27 was destroyed, and the EcoRI site located
at the start of the probe sequence was mutated to a new
BamHI site using the Quikchange site-directed mutagen-
esis strategy. The 50-GATC-30 overhang after BamHI clea-
vage permits sequential labeling of the antisense strand in
a ﬁll-in reaction with biotin-labeled dGTP and
35S-dATP.
To limit PCR ampliﬁcation of the probe sequence from
the isolated heteroduplex, the upstream V3 PCR primer
binding site in the pJN27 plasmid was mutated, reducing
the eﬃciency of ampliﬁcation by 1000-fold. The ﬁnal
sequence of the V3 Mut-1 probe at the upstream V3
boundary was 50-GATCCGGCTTGAATCTGTAGAAA
TTAATTGTACACGACAAAA...-30. The ﬁnal probe
sequence at the downstream V3 boundary in the probe
is 50-...CATTGTAACATTAGTAGAGCAAAAAAGCC
GAATTAATTCTGCA-30. Introduced nucleotide changes
are indicated by bolded and underlined letters, and
plasmid sequence included in the V3 probe is shown in
italics.
The pR-EBm protease probe plasmid was generated
from the multiple-site-speciﬁc HTA probe pR-EB pre-
viously described by Resch et al. (15). The site-directed
mutagenesis procedure described above was used to
generate the pR-EBm probe. The probe was modiﬁed
for this study by introducing base mismatches in the
upstream PCR primer binding site to limit ampliﬁcation
from the probe sequence from the isolated heteroduplex.
Additionally, a BamHI site was introduced at the 30 end
to accommodate biotin- and radiolabeling of the sense
strand. The 50 probe sequence is 50-TATGGATAACT
AAAGGAAGCTCTATTAGATACTGGCT ...-30, and
the 30 probe sequence is 50-... TCAGATTGGTTGCA
CTTTAAATTTTCCATCG(biotin-dGTP)(S
35-dATP)-30.
Introduced nucleotide changes are indicated by bolded,
underlined letters, and plasmid sequence included in the
probe is shown in italics.
Probe labeling
The V3 Mut-1 probe plasmid (10 mg) was digested with
BamHI (60 ml total volume) followed by a ﬁll-in reaction
with 4 nmol Biotin-11-dGTP (PerkinElmer), 0.05mCi
[a-
35S]-dATP (1250Ci/mmol; PerkinElmer), 20 U of the
Klenow fragment of DNA polymerase I and 0.6mlo f1 M
DTT. The reaction was incubated for 15min at room
temperature followed by the addition of 1.4ml 0.5M
EDTA and heat inactivation for 15min at 808C. The
excess nucleotides were then removed using the Qiagen
PCR Puriﬁcation kit (Qiagen), and the V3 Mut-1 probe
was released from the vector by PstI digestion. The
pR-EBm probe plasmid was labeled using the same pro-
cedure, except that after puriﬁcation the pR-EBm probe
was released from the vector by NdeI digestion.
RNA Isolation, RT-PCR andHTA
ProceduresforviralRNAisolationfromplasma,RT-PCR,
and the HTA were conducted as previously described
(14,15). Brieﬂy, viral RNA was isolated from blood
plasma (140ml) using the QIAmp Viral RNA kit
(Qiagen). Reverse transcription and PCR ampliﬁcation of
the 140bp V3 amplicon were conducted with 5 ml of puri-
ﬁed RNA (from 50ml column elution volume) and the pri-
mers HIVV3F [Hxb2 7142-7171 (50-GAATCTGTAG
AAATTAATTGTACAAGACCC-30)] and HIVV3R
[Hxb2 7239-7211 (50-CCATTTTGCTCTACTAATGTTA
CAATGT-30)] by using the Qiagen One-Step RT-PCR kit
(Qiagen) as per manufacturer’s instructions. Ampliﬁcation
of a 247-bp region of pro was conducted using the proce-
durestatedaboveandtheprimersPRAMPUP[Hxb22305-
2334 (50-AACTAAAGGAAGCTCTATTAGATACAGG
AG-30)] and PRAMPDW [Hxb2 2551-2525 (50-GGAAA
ATTTAAAGTGCAACCAATCTGA-30)]. Heteroduplex
annealing reactions consisted of 1mlo f1 0   annealing
buﬀer(14,16),0.1mgbiotinylatedandradioactively-labeled
probe and 8ml of unpuriﬁed PCR product. The reactions
were denatured and the DNA was annealed at room
temperature to allow heteroduplex formation. The hetero-
duplexes were separated by native polyacrylamide gel
electrophoresis (as described in refs 14 and 15), and the
separated heteroduplexes were visualized by autoradiogra-
phy. The relative abundance of each detected heteroduplex
was determined by exposing the HTA gel to a phosphor-
imager screen, and the percent abundance of each variant
was calculated using ImageQuant software (Molecular
Dynamics).
Band extraction, DNA purification and sequence analysis
The dried HTA gels were aligned with the exposed auto-
radiography ﬁlm, and the desired labeled bands were
excised from the gel. The gel fragment was transferred
to a sterile 1.5ml microcentrifuge tube. Crush and Soak
buﬀer (120ml; 500mM NH4OAc, 0.1% SDS, 0.1mM
EDTA) was then added, and the tubes were incubated
at 378C overnight. After incubation, the tubes were
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gel fragments, and the supernatants were transferred to
a 96-well PCR plate. Streptavidin-coated Dynabeads
(Invitrogen) (5ml per reaction) were washed twice then
resuspended in the same volume in 2  B&W buﬀer
[10mM Tris–HCl (pH 7.5), 1mM EDTA, 2M NaCl].
The bead suspension was then aliquoted into a clean
96-well PCR plate (5ml per well). The plate containing
the beads was placed on the magnet for 1min and the
supernatant was removed. The plate was removed from
the magnet, and the beads were resuspended in 80mlo f
2  B&W buﬀer. An equal volume (80ml) of the gel-
extracted heteroduplex product was then added to the
beads. The plate was then incubated for 17min at
room temperature in a MixMate shaker (Eppendorf) at
700r.p.m. to prevent the beads from settling. After the
incubation, the plate was placed on the magnet for
2min, and the supernatant was removed and discarded.
The beads were washed three times in 1  B&W buﬀer
(20ml), and then washed twice in 1  SSC (pH 7.0;
50ml). After the last wash, the beads were resuspended
in 20ml of freshly prepared 0.15M NaOH and incubated
for 5min at room temperature to denature the heterodu-
plexes. The plate was then placed on the magnet for 1min,
and the supernatant containing the denatured query
strand was transferred to a clean 96-well PCR plate. The
supernatant was neutralized by adding 2.4mlo f1 0   TE
(pH 7.5) and 2.4ml of 1.25M acetic acid.
The puriﬁed query strand DNA was then ampliﬁed
with the Platinum Taq DNA Polymerase High Fidelity
PCR kit (Invitrogen) as per the manufacturer’s instruc-
tions, using 2 ml DNA and the PCR primers described
above. The V3 sequencing primers are V3SeqF [Hxb2
7147-7176 (50-TGTAGAAATTAATTGTACAAGACCC
AACAA-30)] and V3SeqR [Hxb2 7234-7205 (50-TTTGCT
CTACTAATGTTACAATGTGCTTGT-30)]. The prote-
ase PCR primers described above were used to sequence
theproPCRproducts.Bulksequencingwasalsoconducted
on the original PCR products ampliﬁed from viral RNA.
GenBank accession numbers FJ347037-FJ347099.
RESULTS
Biotinylated probes and HTA allow the identification and
recoveryof minor HIV-1 variants from acomplex population
The HTA is capable of separating diverse genetic variants
in a gel-based format (9–11,14–16). We have modiﬁed the
original HTA method to permit direct sequence determi-
nation of the query strand of the target heteroduplex
and adapted the approach to a 96-well plate format. To
accomplish direct sequencing of the query strand we incor-
porated a biotin tag into the probe strand (see Materials
and methods section) to allow for the puriﬁcation of the
labeled heteroduplex followed by the separation of the
query and probe strands (Figure 1).
In this approach a query PCR product is generated,
annealed to a radiolabeled/biotin-labeled probe, and the
heteroduplexes are resolved by native polyacrylamide gel
electrophoresis. Gel slices containing the labeled hetero-
duplexes are then excised from dried polyacrylamide gel
using X-ray ﬁlm that had been exposed to the gel as a
guide. The excised gel slices are rehydrated and soaked
overnight to recover heteroduplex DNA from the gel
fragments. The biotin-tagged heteroduplexes are then
puriﬁed away from the gel fragments and any unlabeled
co-migrating DNA (i.e. heteroduplexes formed between
the unlabeled PCR products) by binding the labeled het-
eroduplexes to streptavidin-coated magnetic Dynabeads,
Crush & Soak
Buffer
Supernatant
Streptavidin coated
Dynabeads®
probe strand
query strand
Incubate heteroduplexes
with Dynabeads®.  Wash and
remove contaminants. Dilute NaOH
Supernatant
(a)
(b)
(c)
(e)
(d)
Figure 1. The biotin-HTA strategy. (a) The region of interest is PCR ampliﬁed from the HIV-1 genome and mixed with a biotinylated probe to
generate heteroduplexes between the probe and PCR product. The heteroduplexes are then separated by polyacrylamide gel electrophoresis based on
DNA bending. The single-stranded probe band is denoted by the asterisk, and the double-stranded probe band is denoted by double asterisks. The
labeled heteroduplexes are excised from the dried polyacrylamide gel. (b) The gel fragments are soaked overnight to recover heteroduplex DNA from
the gel fragments. (c) The supernatant containing the biotin-tagged heteroduplexes is then incubated with streptavidin-coated magnetic Dynabeads.
The biotin-tagged heteroduplexes bind to the streptavidin-coated magnetic Dynabeads, and contaminants are removed by washing. (d) The query
DNA strand in the heteroduplex is eluted from the probe DNA with dilute NaOH, which allows the probe strand to remain attached to the magnetic
beads. (e) The puriﬁed query strand is then used as template in another round of PCR ampliﬁcation, and the PCR product is sequenced using
standard technology.
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eroduplex is then eluted from the probe DNA with dilute
NaOH, which allows the probe strand to remain attached
to the magnetic beads and thus removed from the solu-
tion. The puriﬁed query DNA strand is then used as the
template in another round of PCR ampliﬁcation, and the
PCR product is sequenced using standard technology.
Below we describe the application of this approach to
the sequence-based identiﬁcation of HIV-1 variants that
enter cells using the CXCR4 coreceptor, and of variants
that encode drug resistance in subjects failing therapy with
a protease inhibitor, in each case resolving these variants
from genotypic mixtures.
Minor X4variants are identified and recovered
using abiotinylated-V3 HTA probe
We analyzed the V3 region of env for 34 HIV-1-infected
subjects with CD4
+ T cell counts <150 cells/ml to test the
ability of our biotin-HTA method to detect and recover
minor V3 variants in complex viral populations. Figure 2a
shows the separation of genotypic mixtures of the V3
region of the env gene in the HTA gel (14,17). We were
able to obtain V3 sequence from 63 of the 69 visible het-
eroduplexes in the polyacrylamide gels, and phosphorima-
ger analysis was used to deﬁne the relative fraction of each
variant. For these subjects the average number of variants
was two variants per subject, and the number of variants
ranged from one (12 subjects) up to ﬁve (one subject).
We used the modiﬁed 11/25 rule (18,19) and the posi-
tion-speciﬁc scoring matrix (PSSM) (20) to predict the
coreceptor usage of these V3 sequences based on the
viral genotype. A total of 63 V3 sequences were generated
for these 34 subjects, of which 48 corresponded to an
R5-using genotype and 15 corresponded to an X4-using
genotype (Figure 2 and data not shown). The biotin-V3
HTA method recorded the presence of minor R5 or X4 V3
variants (deﬁned as <30% of the total population) in 18 of
the 34 subjects, and a total of 26 bands with a relative
abundance of <30% were excised and sequenced. We
obtained sequence for 20 of the bands while we failed to
obtain sequence for six bands. The relative abundance of
the six variants for which sequence was not obtained
ranged from 0.1% to 13% of the total population,
with the failure to obtain usable sequence attributable to
either very low abundance or near co-migration. Of the
20 minor V3 sequences we recovered, nine were classiﬁed
as X4-using viruses. We were able to detect two of these
minor X4 sequences as mixtures in bulk sequence analysis,
while the other seven minor X4 variants were not detected
by bulk sequence analysis due to low relative abundance.
All of the V3 variants that were extracted from the gel
and PCR ampliﬁed migrated to the same position in the
gel as the original band ampliﬁed from viral RNA (data
not shown). One limitation of this procedure is that major
bands in the gel trail upwards, and PCR products of
minor variants that migrate right above a major variant
in the gel may contain a small amount of the major
variant. However, in most cases (55 out of 69 variants)
the V3 sequence obtained from the PCR products had
clean peaks, and the major variant was not detected
in the sequence analysis (data not shown). For the remain-
ing 14 variants that had multiple peaks present in the
sequence analysis, and also displayed a large amount of
the contaminating major variant, puriﬁed samples were
re-ampliﬁed and puriﬁed again to obtain the target
sequence. Using this enrichment method, we were able to
determine the sequence of eight additional variants.
Overall, we were able to obtain clear sequence for  90%
of all bands detected and  75% of all detected bands
representing <30% of the population, and the use of
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2 96 0 NNNTRKSIHIGPGRSLYTTDIIGDIRQ
1551 1 45 0 NNNTRKGIHIGPGRAFYTTGEIIGDIRK
2 55 1 NNNTRRGVYIGPGKAFYTTDRIIGDIRQ
1784 1 100 0 HNNTRKGIHIGPGRAFYATGEIIGDIRQ
1198 1 100 0 NNNTIKGIHIGPGRAFYTTGAIIGDIRQ
1309 1 25 0 NNNTRKSVPIGPGKAFFATGEIIGDIRQ
2 39 0 NNNTRKSVPIGPGSAFFATGDIIGDIRQ
3 36 0 NNNTRKSVPLGPGRVFYTTGDIVGDVRR
1007 1 70 0 NNNTRKGIHMGPGKVFYATGEIIGDIRQ
2 0.1 N/A
3 0.5 1 NNYTKKSITRTPGRVIYTTGKIIGDIKR
4 29.4 1 NNYTKRSITRTPGRVIYTTGKIIGDVKR
A  D T
Figure 2. Identiﬁcation and recovery of minor V3 variants using a biotinylated-V3 HTA. (a) Biotin-V3 HTA gel for nine representative subjects. The
asterisk indicates the single-stranded probe band, double asterisks indicate the double-stranded probe band, the plus sign indicates background bands
and arrowheads indicate shifted heteroduplex bands. (b) The numbered bands were extracted, puriﬁed and sequenced to determine the V3 sequence
of each band. It is important to note that the V3 PCR primers we used to amplify the V3 products extend into the ﬁrst four and the last three amino
acids of the V3 sequence, and the V3 sequences provided in Figure 2 and GenBank (Acc. # FJ347037-FJ347099) do not include these amino acids.
However, to accurately predict coreceptor usage using PSSM we added the JRFL consensus amino acid sequence to the beginning (CTRP) and end
(AHC) of each V3 sequence. The relative abundance (Rel. Ab.) and PSSM score (0=R5-like sequence, 1= 4-like sequence, N/A=not applicable)
for each sequence are listed in (b).
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analysis.
In order to further examine the sensitivity and speciﬁ-
city of the biotin-HTA, several control experiments were
conducted. First, we mixed together two V3 PCR products
at varying ratios and then separated the mixtures using the
biotin-V3 HTA. The bands were then excised from the gel,
puriﬁed and sequenced. In this control experiment, we
were able to obtain sequence from a band that represented
as little as 1.5% of the total population (Figure 3a).
Sequence was not obtained from the band representing
0.5% of the population; however, we did not re-amplify
the product in this case which can allow increased sensi-
tivity of detection, as described above. To address speciﬁ-
city, single genome ampliﬁcation (SGA) (21) of the env
gene was conducted on blood plasma from subject 1314
in order to compare the relative abundance of variants
determined using biotin-HTA to sampling of the viral
population by sequencing individual viral templates. We
generated and sequenced 10 SGA amplicons and com-
pared the V3 regions to the sequences identiﬁed using
the biotin-V3 HTA. The 10 amplicons represented two
migration patterns in the V3-HTA, with seven of the
amplicons having one migration rate (shown as amplicons
1.1 and 1.2 in Figure 3b), and three of the amplicons
having the other migration rate (labeled amplicon 2 in
Figure 3b). This closely approximated the ratio of 73%
and 27% for these two bands as determined by V3-HTA
(Figure 3c), and this result is consistent with a similar
control done previously with a V1/V2-HTA probe (16).
The altered migration of heteroduplexes in the HTA
is based on sequence diﬀerences between the strands,
especially clustered mutations and insertion/deletions,
with variable sensitivity to detect isolated point mutations.
This feature can be seen in the sequence diﬀerences
between the bands that were resolved by the biotin V3-
HTA (amplicons 1 and 2, Figure 3c), but the co-migration
of sequences that diﬀered by only a few nucleotides
(amplicons 1.1 and 1.2, Figure 3c). In this case the level
of variability in the isolated HTA band was revealed as
a mixed peak in the sequence chromatogram when that
band was isolated and sequenced (data not shown).
Minor proteasedrug-resistant variants are detected
using abiotinylated-protease HTA probe
We have applied the biotin-HTA to separate HIV-1 pro
variants, encoding the viral protease, and to sequence
these variants to detect mutations that confer resistance
to protease inhibitors. The biotin-protease HTA is a mod-
iﬁcation of the previously described multiple site-speciﬁc
HTA (MSS-HTA) (15) (see Materials and methods sec-
tion) with the probe designed to query mutations at pro-
tease codon positions 46, 48, 54, 82, 84 and 90. We used
both our own bulk sequence analysis and the biotin-
protease HTA to screen 19 subjects who had previously
failed therapy that included the protease inhibitor IDV.
A total of 10 subjects had no primary resistance muta-
tions by either method, although some had viral genotypes
that included polymorphic mutations that can become
enriched with therapy (22) (data not shown) (Stanford
Database, http://hivdb.stanford.edu/). The remaining
nine subjects all exhibited primary resistance mutations
(Stanford database, http://hivdb.stanford.edu/). For three
of these subjects we detected a homogeneous population
by both methods (data not shown). The results of the
biotin-HTA analysis and the bulk sequence analysis for
the remaining six subjects are shown in Figure 4.
Bulk sequence analysis was able to identify mutations in
variants that comprised as little as 28% of the population
(Figure 4, subject 18, band 1), but also missed mutations
that existed in variants making up as much as 45% of the
population (Figure 4, subject 4, band 1), perhaps due to
poor incorporation of the chain terminating nucleotide at
that position. In contrast, using the biotin-HTA approach
we were able to identify primary resistance mutations at
the query positions in three subjects (subject 4, band 1;
subject 16, band 1; and subject 22, bands 1 and 2) that
were not detected in bulk sequencing (Figure 4). Exclusive
linkage between resistance mutations I54V and V82A was
established in one subject (Figure 4, subject 18, band 1).
The least abundant variant we identiﬁed comprised 4% of
the total population (Figure 4b, subject 16, band 3),
although this variant diﬀered by only one synonymous
change from the bulk sequence (data not shown).
Resistance mutations were sometimes identiﬁed as mix-
tures in excised bands (Figure 4, subject 4, band 1; subject
16, band 1; subject 18, band 4). This can result from either
trailing of products from a major lower band, or, in the
case of positions that the probe was not designed to query,
the inability of the probe to distinguish between variants
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Figure 3. Examination of the sensitivity of the biotin-V3 HTA.
(a) Mixtures of two V3 PCR products were separated by the
biotin-V3 HTA. The bands were cut from the gel, puriﬁed and
sequenced. The plus sign indicates bands for which sequence was
obtained, and the minus signindicates a band for which the sequence
was not obtained. The asterisk indicates the single-stranded probe
band, and double asterisks indicate the double-stranded probe band.
(b and c) SGA of the env gene was conducted on Subject 1314. The
migration of three diﬀerent SGA-V3 PCR products and the original
1314 V3 PCR product are shown in (b). The V3 amino acid sequence
of the extracted bands and the SGA amplicons, the relative abundance
(Rel. Ab.) and number of SGA amplicons (N) are listed in (c).
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bands 1–3). Despite existing as mixtures in these cases,
resistance mutations were enriched, and therefore
detected, in electrophoretically separated variants when
they were otherwise not detected by bulk sequence analy-
sis. One subject had a resistance mutation (subject 15,
V82A; data not shown) that was detected in a separate
clinically approved bulk sequence analysis protocol but
not in the HTA analysis, while three other subjects
displayed resistance mutations that were detected by
HTA but not by the clinically approved analysis
(Figure 4, subject 4, V82A; subject 16 and 18, I54V).
DISCUSSION
The biotin-HTA allows for the detection and direct
sequence analysis of multiple variants in a complex popu-
lation. Using the biotin-HTA targeting the V3 region of
env, we were able to detect and directly determine the
sequence of 20 minor (<30% abundance) R5 and X4
viral variants, of which 45% were classiﬁed as X4-using
viruses. In addition, we used a biotin-protease HTA to
detect and sequence speciﬁc drug resistance mutations in
pro in 19 subjects failing treatment with an HIV-1 protease
inhibitor. Fifteen of the 19 subjects had matching geno-
types for the clinical screening data and the HTA analysis,
while three subjects displayed resistance mutations that
were detected by HTA but not by a clinically approved
bulk sequence analysis.
An RNA heteroduplex generator-tracking assay (RNA-
HTA) has been developed that uses a degradable RNA
probe to allow direct sequence analysis of the query
strand, which was tested by examining HIV-1 variants
with drug-resistance mutations in the protease coding
domain (23). Using this method, variants that comprised
1% of the total population were identiﬁed and subjected
to sequence analysis. One drawback of the RNA-HTA
method is that unlabeled DNA–DNA heteroduplexes
generated from variants within the PCR product can
co-migrate with the labeled RNA–DNA heteroduplexes,
going undetected in the gel but giving rise to sequence
mixtures during the subsequent ampliﬁcation and
sequence analysis. Our biotin-HTA method introduces
the ability to purify speciﬁcally the biotin/radiolabeled
probe: PCR product heteroduplexes from unlabeled
PCR product heteroduplexes that might migrate to the
same location in the polyacrylamide gel. Similar to what
Kapoor et al. (23) saw in their studies, we also ﬁnd that
major variants trail upward in the gel and can be detected
in the PCR products extracted from upper bands. In the
case that an unreadable sequence is detected using the
biotin-HTA procedure, it is possible to simply re-amplify
the now enriched mixture and run another biotin-HTA
followed by sequence analysis.
In a control experiment we were able to obtain sequence
information from a band that comprised 1.5% of the
signal, and as seen previously (16), the HTA provides
sampling that is similar to that obtained by other methods
but has the advantage of being able to query many more
templates than these other methods (Figure 3). During the
analysis of the subject samples, we were able to obtain
the sequence of a variant that represented 0.5% of the
total population (subject 1007, Figure 2b) by running
the extracted V3 PCR product on another biotin-HTA
and re-amplifying the puriﬁed product, thus allowing for
further enrichment of the minor variant. A useful compar-
ison of the potential utility of the HTA is as follows. If one
were to sequence 300 clones (assuming they are derived
from independent templates in the PCR ampliﬁcation),
Figure 4. Detection of minor protease inhibitor resistance mutations
using a biotinylated-protease HTA. (a) Protease-speciﬁc MSS-HTA
gel for six representative subjects. Double asterisks indicate the
double-stranded probe band and arrowheads indicate shifted hetero-
duplex bands. (b) Numbered bands were extracted and sequenced to
identify the predicted amino acid at the positions indicated. For each
subject, the bulk PCR sequence is listed above the band sequences.
Mixtures are indicated where identiﬁed by sequencing. The rela-
tive abundance of each band is listed in the right-most column as
a percentage of the total. The amino acids inferred from the bulk
sequence for Subject 4 represent the wild-type consensus. Amino acid
positions which the probe was designed to query are in bold (46, 48,
54, 82, 84, 90). Shaded amino acids represent positions at which
heterogeneity was identiﬁed by HTA but not by bulk sequence
analysis.
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a 1% level. In this case detection of presence is more
robust than the estimate of relative abundance; also, the
amount of work essentially increases linearly as the
number of clones analyzed increases. HTA is able to
detect signals in the 1% range in the gel-based detection
system. However, sampling quality can be signiﬁcantly
better since this approach is not limited by the number
of templates sampled, i.e. sampling 300 templates is as
easy as sampling 3000 templates. This allows the HTA
approach to measure more accurately the relative abun-
dance of even minor species in those circumstances where
larger numbers of templates are available to be sampled,
and to validate their abundance by comparing repeat
ampliﬁcations.
Diﬀerent HIV-1 entry inhibitors are being explored
as possible drugs to block HIV-1 infection and to treat
current infections. Several CCR5-inhibitors are approved
or in development for the treatment of HIV-1 infec-
tion, including maraviroc (Pﬁzer) (24,25) and vicriviroc
(Schering Plough) (26,27). CCR5-inhibitors work by bind-
ing the CCR5 coreceptor to block the entry of HIV-1.
CXCR4-using viruses are naturally resistant to these
CCR5-binding drugs and therefore this class of inhibi-
tor is not indicated for subjects with X4 variants. In
addition, coreceptor switching has been documented
in several subjects using CCR5-inhibitors, although the
level of CXCR4-emerging viruses was lower than expected
(25,28). In the subjects where CXCR4-using viruses
emerged after treatment with a CCR5 inhibitor, phyloge-
netic analysis showed that these variants were a result of
the outgrowth of a minor CXCR4-using variant that
was present prior to the initiation of drug therapy (28).
The biotin-V3 HTA that we have developed can detect
and genotype minor V3 variants in the range of 1.5%
of the total HIV-1 population, and could be used as
an initial genotypic screen for CXCR4-using variants in
people considering CCR5-inhibitor drug therapy.
Additionally, genotypic testing for the presence of
resistance mutations is the standard-of-care for people
initiating and failing therapy (Guidelines for the use
of antiretroviral agents in HIV-1-infected adults and
adolescents, U.S. D.H.H.S., http://www.aidsinfo.nih.gov/
ContentFiles/AdultandAdolescentGL.pdf). The biotin-
protease HTA provides an example where complex
mixtures of sequences can be examined with greater sen-
sitivity to detect resistance mutations. The biotin-HTA
methods used here for the detection and direct sequence
analysis of minor HIV-1 variants should be applicable
to other complex viral and non-viral populations where
increased sensitivity of detection of minor genetic variants
is important.
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